Kazlauskas H - Search Results

1

Nonthyroidal Illness Syndrome in Ischaemic Stroke Patients is Associated with Increased Mortality.

Taroza S, Rastenytė D, Podlipskytė A, Kazlauskas H, Mickuvienė N. Taroza S, et al. Among authors: kazlauskas h. Exp Clin Endocrinol Diabetes. 2020 Dec;128(12):811-818. doi: 10.1055/a-0915-2015. Epub 2019 Jun 3. Exp Clin Endocrinol Diabetes. 2020. PMID: 31158897

2

Role of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and inteleukin-6 in predicting a poor outcome after a stroke.

Bunevicius A, Kazlauskas H, Raskauskiene N, Mickuviene N, Ndreu R, Corsano E, Bunevicius R. Bunevicius A, et al. Among authors: kazlauskas h. Neuroimmunomodulation. 2015;22(6):365-72. doi: 10.1159/000381218. Epub 2015 May 9. Neuroimmunomodulation. 2015. PMID: 25967464

3

Stroke mortality trends in the population of Klaipėda from 1994 to 2008.

Kazlauskas H, Raškauskienė N, Radžiuvienė R, Janušonis V. Kazlauskas H, et al. Medicina (Kaunas). 2011;47(9):512-9. Epub 2011 Dec 5. Medicina (Kaunas). 2011. PMID: 22156606 Free article.

4

Ischemic stroke functional outcomes are independently associated with C-reactive protein concentrations and cognitive outcomes with triiodothyronine concentrations: a pilot study.

Bunevicius A, Kazlauskas H, Raskauskiene N, Janusonis V, Bunevicius R. Bunevicius A, et al. Among authors: kazlauskas h. Endocrine. 2014 Mar;45(2):213-20. doi: 10.1007/s12020-013-9958-2. Epub 2013 Apr 21. Endocrine. 2014. PMID: 23605905

5

Twenty years trends in mortality rates from stroke in Klaipeda.

Kazlauskas HA, Raskauskiene N, Radziuviene R, Janusonis V. Kazlauskas HA, et al. Brain Behav. 2016 Jun 2;6(8):e00499. doi: 10.1002/brb3.499. eCollection 2016 Aug. Brain Behav. 2016. PMID: 27547501 Free PMC article.

6

The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.

Sandset EC, Bath PM, Boysen G, Jatuzis D, Kõrv J, Lüders S, Murray GD, Richter PS, Roine RO, Terént A, Thijs V, Berge E; SCAST Study Group. Sandset EC, et al. Lancet. 2011 Feb 26;377(9767):741-50. doi: 10.1016/S0140-6736(11)60104-9. Lancet. 2011. PMID: 21316752 Clinical Trial.

7

Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia.

Tanaseanu C, Milutinovic S, Calistru PI, Strausz J, Zolubas M, Chernyak V, Dartois N, Castaing N, Gandjini H, Cooper CA; 313 Study Group. Tanaseanu C, et al. BMC Pulm Med. 2009 Sep 9;9:44. doi: 10.1186/1471-2466-9-44. BMC Pulm Med. 2009. PMID: 19740418 Free PMC article. Clinical Trial.

8

Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience.

Dartois N, Castaing N, Gandjini H, Cooper A; Tigecycline 313 Study Group. Dartois N, et al. J Chemother. 2008 Oct;20 Suppl 1:28-35. doi: 10.1179/joc.2008.20.Supplement-1.28. J Chemother. 2008. PMID: 19036672 Clinical Trial.

9

Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.

Tanaseanu C, Bergallo C, Teglia O, Jasovich A, Oliva ME, Dukart G, Dartois N, Cooper CA, Gandjini H, Mallick R; 308 Study Group; 313 Study Group. Tanaseanu C, et al. Diagn Microbiol Infect Dis. 2008 Jul;61(3):329-38. doi: 10.1016/j.diagmicrobio.2008.04.009. Epub 2008 May 27. Diagn Microbiol Infect Dis. 2008. PMID: 18508226 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9 results

Search Page

Filters